IRIS
BOCCARDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 31.321
Totale 31.321
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 31.321
Totale 31.321
Salva come PNG Salva come JPEG
Città #
Genova 25.260
Rapallo 3.374
Genoa 2.518
Vado Ligure 104
Bordighera 65
Totale 31.321
Salva come PNG Salva come JPEG
Nome #
A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature 151
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 150
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 150
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 149
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 147
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy 146
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 145
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 143
Apalutamide treatment and metastasis-free survival in prostate cancer 139
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 137
A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature 136
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 136
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma 135
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 132
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 132
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 130
Differential expression of nuclear lamins in normal and cancerous prostate tissues 130
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 130
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. 129
Ovarian ablation in early breast cancer: overview of the randomised trials. 127
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 126
Adjuvant therapy for patients with node negative breast cancer. 125
Alternating chemo-radiotherapy in bladder cancer: a conservative approach. 125
Leiomyosarcoma of the broad ligament: a case report and review of literature. 125
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. 125
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 125
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study 125
Adjuvant chemotherapy of bladder cancer. 124
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 124
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report 123
Switching to aromatase inhibitors in early breast cancer. 123
Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. 123
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer 122
Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. 121
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 121
Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. 121
Combinations of hormonal therapy and chemotherapy 120
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. 119
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 119
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 119
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 119
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. 118
Re: j. Alfred witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8. 118
Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix. 118
Somatuline and tamoxifen in postmenopausal breast cancer patients. 117
Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. 117
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 117
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. 117
D-TRP-6-LH-RH treatment of advanced prostatic cancer 117
Carboplatin in advanced hormone refractory prostatic cancer patients. 116
Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. 116
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 116
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 116
Presence and distribution of growth factors in breast cyst fluid. 115
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 115
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 115
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 115
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. 114
Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. 114
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 114
Management of young women with early breast cancer 114
Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer 113
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. 113
Oral vinorelbine in the treatment of non-small-cell lung cancer. 113
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 113
R75251 in prostate cancer patients in progression after first-line hormonal treatment. 112
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 112
Fertility, sexuality and cancer in young adult women 112
Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. 111
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. 111
Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment 111
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 111
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 111
Nafarelin acetate and benign prostatic hyperplasia. 110
Endothelial cells increase the radiosensitivity of oropharyngeal squamous carcinoma cells in collagen gel 110
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 110
Ifosfamide in urologic cancer. 109
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. 109
Belagenpumatucel-L for the treatment of non-small cell lung cancer 109
Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer 108
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 108
Management of breast cancer: Is there a role for Somatostatin and its analogs? 108
Italian national consensus conference on prostate cancer screening (Florence, May 17, 2003)--final consensus document. 108
Urethral stricture and scrotal abscess: a rare case presentation of penile cancer and review of the literature 108
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial 107
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 107
Phase II study of navelbine in advanced renal cell carcinoma. 106
Fibronectin concentration in the plasma of patients with malignant and benign breast disease. 106
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen. Results of the GROCTA trial. 106
Bone metastases from prostate cancer: hormonal therapy 106
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 106
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials 106
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 106
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. 106
Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients 105
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. 105
May adjuvant therapy play a role for the management of renal cell carcinoma? A review of literature and ongoing trials 105
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. 105
Clinical evaluation of new tumor-associated antigens. 104
The MAINSAIL trial: an expected failure 104
Totale 11.897
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.162
article - articoli 78.084
book - libri 387
conference - conferenze 140
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 7.551
Totale 172.324
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.646 0 213 381 479 839 907 1.478 610 766 1.603 1.062 308
2020/20212.770 153 267 210 287 156 382 102 215 233 284 217 264
2021/20224.214 105 289 202 604 152 290 132 1.154 233 379 96 578
2022/20234.052 409 225 46 383 741 831 7 272 729 30 317 62
2023/20241.832 85 294 46 205 154 317 99 113 84 61 94 280
2024/2025185 130 55 0 0 0 0 0 0 0 0 0 0
Totale 32.008